Brief: Aurobindo Pharma Receives USFDA Approval For Dextromethorphan Polistirex Extended-Release Oral Suspension
17/04/2026 14:02
April 17 (Reuters) - Aurobindo Pharma Ltd ARBN.NS: AUROBINDO PHARMA- RECEIVES USFDA APPROVAL FOR DEXTROMETHORPHAN POLISTIREX EXTENDED-RELEASE ORAL SUSPENSION, 30 MG/5 ML (OTC) AUROBINDO PHARMA - PRODUCT TO BE LAUNCHED IN Q2FY27 Source text: ID:nBSE4wprRS Further company coverage: ARBN.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurobindo Pharma
See all newsBrief: Aurobindo Pharma Gets Tax Order Confirming Total Disputed Amount 46 Million Rupees
India's Aurobindo Pharma falls after US FDA flags observation at Telangana facility
Brief: Aurobindo Pharma Says US FDA Inspected API Manufacturing Facility Of Unit Apitoria Pharma
Brief: Aurobindo Pharma Gets USFDA Final Approval For Beclomethasone Dipropionate HFA Inhalation Aerosol
Brief: Aurobindo Pharma Says US FDA Inspected Unit-IV Of Apitoria Pharma From September 7 To September 11